Treatment with New Class of Drugs Shows Improvement in 20 Dermatological Conditions
NEW YORK, NY, UNITED STATES, July 23, 2024 /EINPresswire.com/ -- Janus Kinase (JAK) inhibitors interfere with the JAK-STAT signaling pathway, which can correct problems of inflammation and immune function. Upadacitinib, a JAK inhibitor, has been …